C. Flannery (Durham, US)
BioventusPresenter Of 1 Presentation
P206 - Quantitative Analyses of a Novel Placental Tissue Biologic (PTP-001) Compared with Platelet Rich Plasma (PRP)
Abstract
Purpose
Non-surgical options for the treatment of osteoarthritis (OA) represent an urgent unmet medical need. PTP-001 is a novel placental tissue particulate (injectable) which is in development as a biologic for the treatment of OA knee pain and impaired function. We performed quantitative analyses of growth factor content, and bioactivity in cell-based assays, to compare PTP-001 with two commonly utilized PRP preparations.
Methods and Materials
PTP-001 was prepared from donated placental tissues. LP-PRP or LR-PRP preparations were activated with CaCl2. PTP-001 eluates and PRP samples were assayed by ELISAs for growth factor content, and were tested in a macrophage anti-inflammatory assay. Samples were also assessed in a co-culture system comprising human articular chondrocytes and synoviocytes. Following stimulation with PMA and subsequent treatment with PTP-001 eluates or PRP preparations, total RNA from cell compartments was analyzed by Q-PCR.
Results
Quantification of key growth factors illustrative of diverse mechanisms of action confirmed the interdonor consistency of PTP-001 (Fig. 1a), whereas the PRP preparations were more variable. Furthermore, IL-1Ra was undetectable for LP-PRP, and bFGF was similarly undetectable for either PRP preparation. PTP-001 demonstrated a significant (>80%) reduction in macrophage TNF-alpha production (Fig. 1b) and a similar effect was observed for LR-PRP, although LP-PRP was ineffective in this assay. Q-PCR analysis of a number of disease-relevant genes (e.g. aggrecan, COL2, HAS2, ADAMTS5) revealed no significant differences between control cultures and treatment groups. However, for cells exposed to PTP-001 or LR-PRP, gene expression of the principal cartilage collagenase, MMP-13, was significantly reduced in the synoviocyte compartment (Fig. 1c).
Conclusion
PTP-001 appears to represent a more consistent source of beneficial growth factors, and may have a greater capacity to reduce inflammatory and catabolic processes, in comparison to PRP preparations. Development of PTP-001 as a regulated biologic product may represent a novel approach for the treatment of OA and other musculoskeletal conditions.
Presenter Of 1 Presentation
P206 - Quantitative Analyses of a Novel Placental Tissue Biologic (PTP-001) Compared with Platelet Rich Plasma (PRP)
Abstract
Purpose
Non-surgical options for the treatment of osteoarthritis (OA) represent an urgent unmet medical need. PTP-001 is a novel placental tissue particulate (injectable) which is in development as a biologic for the treatment of OA knee pain and impaired function. We performed quantitative analyses of growth factor content, and bioactivity in cell-based assays, to compare PTP-001 with two commonly utilized PRP preparations.
Methods and Materials
PTP-001 was prepared from donated placental tissues. LP-PRP or LR-PRP preparations were activated with CaCl2. PTP-001 eluates and PRP samples were assayed by ELISAs for growth factor content, and were tested in a macrophage anti-inflammatory assay. Samples were also assessed in a co-culture system comprising human articular chondrocytes and synoviocytes. Following stimulation with PMA and subsequent treatment with PTP-001 eluates or PRP preparations, total RNA from cell compartments was analyzed by Q-PCR.
Results
Quantification of key growth factors illustrative of diverse mechanisms of action confirmed the interdonor consistency of PTP-001 (Fig. 1a), whereas the PRP preparations were more variable. Furthermore, IL-1Ra was undetectable for LP-PRP, and bFGF was similarly undetectable for either PRP preparation. PTP-001 demonstrated a significant (>80%) reduction in macrophage TNF-alpha production (Fig. 1b) and a similar effect was observed for LR-PRP, although LP-PRP was ineffective in this assay. Q-PCR analysis of a number of disease-relevant genes (e.g. aggrecan, COL2, HAS2, ADAMTS5) revealed no significant differences between control cultures and treatment groups. However, for cells exposed to PTP-001 or LR-PRP, gene expression of the principal cartilage collagenase, MMP-13, was significantly reduced in the synoviocyte compartment (Fig. 1c).
Conclusion
PTP-001 appears to represent a more consistent source of beneficial growth factors, and may have a greater capacity to reduce inflammatory and catabolic processes, in comparison to PRP preparations. Development of PTP-001 as a regulated biologic product may represent a novel approach for the treatment of OA and other musculoskeletal conditions.